Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 1174-1182

  Andersen, Anders H ^a,b   Hardy, Peter A ^a,b   Forman, Eric ^a   Gerhardt, Greg A ^a   Gash, Don M ^a   Grondin, Richard C ^a   Zhang, Zhiming ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aging; Apomorphine; MPTP; Parkinsonism; Pharmacologic MRI; Raclopride; SCH23390

Indexed keywords

ADULT; AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; DENERVATION; DIAGNOSTIC IMAGING; FEMALE; GLOBUS PALLIDUS; MIDDLE AGED; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHARMACOLOGICAL NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOLOGICAL PROCEDURES; PUTAMEN; RHESUS MONKEY; AGING; ANIMAL; CHEMICALLY INDUCED; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; RACLOPRIDE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGING; ANIMALS; APOMORPHINE; BASAL GANGLIA; BENZAZEPINES; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGENTS; FEMALE; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; RACLOPRIDE;

EID: 84922800643     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.014     Document Type: Article

References (70)

1. Andersen A.H., Zhang Z., Avison M.J., Gash D.M. Automated segmentation of multispectral brain MR images. J. Neurosci. Methods 2002, 122:13-23.
2. Antonini A., Leenders K.L. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Ann. N. Y. Acad. Sci. 1993, 695:81-85.
3. Backman L., Ginovart N., Dixon R.A., Wahlin T.B., Wahlin A., Halldin C., Farde L. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am. J. Psychiatry 2000, 157:635-637.
4. Backman L., Lindenberger U., Li S.C., Nyberg L. Linking cognitive aging to alterations in dopamine neurotransmitter functioning: recent data and future avenues. Neurosci. Biobehav. Rev. 2010, 34:670-677.
5. Bannon M.J., Poosch M.S., Xia Y., Goebel D.J., Cassin B., Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:7095-7099.
6. Benhamou L., Bronfeld M., Bar-Gad I., Cohen D. Globus Pallidus external segment neuron classification in freely moving rats: a comparison to primates. PLoS One 2012, 7:e45421.
7. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., Evans D.A. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med. 1996, 334:71-76.
8. Bhatia K.P., Marsden C.D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994, 117(Pt 4):859-876.
9. Bokobza B., Ruberg M., Scatton B., Javoy-Agid F., Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 1984, 99:167-175.
10. Buchman A.S., Shulman J.M., Nag S., Leurgans S.E., Arnold S.E., Morris M.C., Schneider J.A., Bennett D.A. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann. Neurol. 2012, 71:258-266.
11. Carey R.J., Huston J.P., Muller C.P. Pharmacological inhibition of dopamine and serotonin activity blocks spontaneous and cocaine-activated behaviour. Prog. Brain Res. 2008, 172:347-360.
12. Cass W.A., Grondin R., Andersen A.H., Zhang Z., Hardy P.A., Hussey-Andersen L.K., Rayens W.S., Gerhardt G.A., Gash D.M. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiol. Aging 2007, 28:258-271.
13. Cersosimo M.G., Koller W.C. The diagnosis of manganese-induced parkinsonism. Neurotoxicology 2006, 27:340-346.
14. Chen Q., Andersen A.H., Zhang Z., Ovadia A., Gash D.M., Avison M.J. Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI. Magn. Reson. Imaging 1996, 14:469-476.
15. Chen Y.C., Choi J.K., Andersen S.L., Rosen B.R., Jenkins B.G. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2005, 180:705-715.
16. Cooper J., Bloom F.E., Roth R.H. The biochemical basis of neuropharmacology 1996, Oxford Univ. Press, New York.
17. Darbin O. The aging striatal dopamine function. Parkinsonism Relat. Disord. 2012, 18:426-432.
18. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J.M., Alperovitch A., Rocca W.A. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 62:10-15.
19. Ding F., Luan L., Ai Y., Walton A., Gerhardt G.A., Gash D.M., Grondin R., Zhang Z. Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys. Exp. Neurol. 2008, 212:431-439.
20. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., Holden J.E., Kordower J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 1998, 401:253-265.
21. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
22. Galvan A., Wichmann T. Pathophysiology of parkinsonism. Clin. Neurophysiol. 2008, 119:1459-1474.
23. Gerhardt G.A., Cass W.A., Henson M., Zhang Z., Ovadia A., Hoffer B.J., Gash D.M. Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey. Neurobiol. Aging 1995, 16:939-946.
24. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem. 2002, 80:168-177.
25. Goldberg J.A., Bergman H. Computational physiology of the neural networks of the primate globus pallidus: function and dysfunction. Neuroscience 2011, 198:171-192.
26. Hammerer D., Eppinger B. Dopaminergic and prefrontal contributions to reward-based learning and outcome monitoring during child development and aging. Dev. Psychol. 2012, 48:862-874.
27. Harada N., Nishiyama S., Satoh K., Fukumoto D., Kakiuchi T., Tsukada H. Age-related changes in the striatal dopaminergic system in the living brain: a multiparametric PET study in conscious monkeys. Synapse 2002, 45:38-45.
28. Hardy P.A., Gash D., Yokel R., Andersen A., Ai Y., Zhang Z. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J. Magn. Reson. Imaging 2005, 21:118-127.
29. Hazrati L.N., Parent A., Mitchell S., Haber S.N. Evidence for interconnections between the two segments of the globus pallidus in primates: a PHA-L anterograde tracing study. Brain Res. 1990, 533:171-175.
30. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 1987, 45:19-34.
31. Hyam J.A., Joint C., Green A.L., Aziz T.Z. Comparison of contralateral pallidotomy vs. pallidal stimulation after prior unilateral pallidotomy for Parkinson's disease. Neuromodulation 2011, 14:117-122. discussion 122.
32. Irwin I., DeLanney L.E., McNeill T., Chan P., Forno L.S., Murphy G.M., Di Monte D.A., Sandy M.S., Langston J.W. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 1994, 3:251-265.
33. Ishibashi K., Ishii K., Oda K., Kawasaki K., Mizusawa H., Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 2009, 63:282-290.
34. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 2004, 24:9553-9560.
35. Kinoshita T., Sugihara S., Matsusue E., Fujii S., Ametani M., Ogawa T. Pallidoreticular damage in acute carbon monoxide poisoning: diffusion-weighted MR imaging findings. AJNR Am. J. Neuroradiol. 2005, 26:1845-1848.
36. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
37. Kobari M., Fukuuchi Y., Shinohara T., Nogawa S., Taahashi K. Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease. Arch. Neurol. 1992, 49:725-730.
38. Laplane D., Levasseur M., Pillon B., Dubois B., Baulac M., Mazoyer B., Tran Dinh S., Sette G., Danze F., Baron J.C. Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. A neuropsychological, magnetic resonance imaging and positron tomography study. Brain 1989, 112(Pt 3):699-725.
39. Levy R., Hazrati L.N., Herrero M.T., Vila M., Hassani O.K., Mouroux M., Ruberg M., Asensi H., Agid Y., Feger J., Obeso J.A., Parent A., Hirsch E.C. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience 1997, 76:335-343.
40. Louis E.D., Bennett D.A. Mild Parkinsonian signs: An overview of an emerging concept. Mov Disord. 2007, 22:1681-1688.
41. Mahlknecht P., Hotter A., Hussl A., Esterhammer R., Schocke M., Seppi K. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis. 2010, 7:300-318.
42. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., Mizuno Y. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 1994, 168:251-253.
43. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temino B., Mena-Segovia J., Rodriguez M., Olanow C.W. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann. Neurol. 2008, 64(Suppl 2):S30-46.
44. Obeso J.A., Rodriguez-Oroz M.C., Benitez-Temino B., Blesa F.J., Guridi J., Marin C., Rodriguez M. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord. 2008, 23(Suppl 3):S548-559.
45. Obeso J.A., Rodriguez M.C., Gorospe A., Guridi J., Alvarez L., Macias R. Surgical treatment of Parkinson's disease. Baillieres Clin. Neurol. 1997, 6:125-145.
46. Olanow C.W., Good P.F., Shinotoh H., Hewitt K.A., Vingerhoets F., Snow B.J., Beal M.F., Calne D.B., Perl D.P. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996, 46:492-498.
47. Parent A., Cossette M. Extrastriatal dopamine and Parkinson's disease. Adv. Neurol. 2001, 86:45-54.
48. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Brain Res. Rev. 1995, 20:128-154.
49. Pohjalainen T., Rinne J.O., Nagren K., Lehikoinen P., Anttila K., Syvalahti E.K., Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 1998, 3:256-260.
50. Prensa L., Cossette M., Parent A. Dopaminergic innervation of human basal ganglia. J. Chem. Neuroanat. 2000, 20:207-213.
51. Rinne J.O., Laihinen A., Nagren K., Bergman J., Solin O., Haaparanta M., Ruotsalainen U., Rinne U.K. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J. Neurosci. Res. 1990, 27:494-499.
52. Rinne J.O., Laihinen A., Rinne U.K., Nagren K., Bergman J., Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov. Disord. 1993, 8:134-138.
53. Sato F., Lavallee P., Levesque M., Parent A. Single-axon tracing study of neurons of the external segment of the globus pallidus in primate. J. Comp. Neurol. 2000, 417:17-31.
54. Schreckenberger M., Hagele S., Siessmeier T., Buchholz H.G., Armbrust-Henrich H., Rosch F., Grunder G., Bartenstein P., Vogt T. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1128-1135.
55. Shinotoh H., Calne D.B. The use of PET in Parkinson's disease. Brain Cogn. 1995, 28:297-310.
56. Sioka C., Fotopoulos A., Kyritsis A.P. Recent advances in PET imaging for evaluation of Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:1594-1603.
57. Smith C.D., Umberger G.H., Manning E.L., Slevin J.T., Wekstein D.R., Schmitt F.A., Markesbery W.R., Zhang Z., Gerhardt G.A., Kryscio R.J., Gash D.M. Critical decline in fine motor hand movements in human aging. Neurology 1999, 53:1458-1461.
58. Tachibana Y., Kita H., Chiken S., Takada M., Nambu A. Motor cortical control of internal pallidal activity through glutamatergic and GABAergic inputs in awake monkeys. Eur. J. Neurosci. 2008, 27:238-253.
59. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 1998, 155:1325-1331.
60. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., MacGregor R.R., Schlyer D.J., Hitzemann R., Wolf A.P. Measuring age-related changes in dopamine D2 receptors with 11C-raclopride and 18F-N-methylspiroperidol. Psychiatry Res. 1996, 67:11-16.
61. Wang G.J., Volkow N.D., Logan J., Fowler J.S., Schlyer D., MacGregor R.R., Hitzemann R.J., Gur R.C., Wolf A.P. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci. 1995, 56:PL249-253.
62. Welford A.T. Aging and Human Skill 1958, Oxford University Press, Oxford, UK.
63. Wisco J.J., Killiany R.J., Guttmann C.R., Warfield S.K., Moss M.B., Rosene D.L. An MRI study of age-related white and gray matter volume changes in the rhesus monkey. Neurobiol. Aging 2008, 29:1563-1575.
64. Wong D.F., Singer H.S., Brandt J., Shaya E., Chen C., Brown J., Kimball A.W., Gjedde A., Dannals R.F., Ravert H.T., Wilson P.D., Wagner H.N. D2-like dopamine receptor density in Tourette syndrome measured by PET. J. Nucl. Med. 1997, 38:1243-1247.
65. Yantiri F., Andersen J.K. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. IUBMB Life 1999, 48:139-141.
66. Zecca L., Shima T., Stroppolo A., Goj C., Battiston G.A., Gerbasi R., Sarna T., Swartz H.M. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996, 73:407-415.
67. Zhang Z., Andersen A., Grondin R., Barber T., Avison R., Gerhardt G., Gash D. Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage 2001, 14:1159-1167.
68. Zhang Z., Andersen A.H., Ai Y., Loveland A., Hardy P.A., Gerhardt G.A., Gash D.M. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage 2006, 33:636-643.
69. Zhang Z., Andersen A.H., Avison M.J., Gerhardt G.A., Gash D.M. Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys. Brain Res. 2000, 852:290-296.
70. Zhang Z., Zhang M., Ai Y., Avison C., Gash D.M. MPTP-Induced pallidal lesions in rhesus monkeys. Exp. Neurol. 1999, 155:140-149.